Multi-elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy patients

被引:12
|
作者
Susuki, Seiko [1 ]
Ando, Yukio [2 ]
Sato, Takashi [1 ]
Nishiyama, Masami [3 ]
Miyata, Masanori [1 ]
Suico, Mary Ann [1 ]
Shuto, Tsuyoshi [1 ]
Kai, Hirofumi [1 ]
机构
[1] Kumamoto Univ, Dept Mol Med, Grad Sch Pharmaceut Sci, Global COE Cell Fate Regulat Res & Educ Unit, Kumamoto 8620973, Japan
[2] Kumamoto Univ, Grad Sch Med Sci, Dept Diagnost Med, Kumamoto 8600811, Japan
[3] Kumamoto Univ, Inst Resource Dev & Anal, Div Instrumental Anal, Kumamoto 8620973, Japan
来源
关键词
ICP-MS; FAP; amyloid; metals; FAP patients; serum;
D O I
10.1080/13506120802006013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There is accumulating evidence of the involvement of biological metal imbalance in the progression of amyloid diseases such as Alzheimer's, Parkinson's and prion diseases. However, the mineral status in patients affected with familial amyloidotic polyneuropathy (FAP) has not been investigated. It is the aim of this study to determine the metal concentrations in the serum and in the transthyretin (TTR) amyloid fibrils of FAP amyloidogenic TTR (ATTR) V30M patients. Multi-elemental analysis of 17 metals by high-resolution inductively coupled plasma mass spectrometry (ICP-MS) revealed a significant decrease of the metals Fe, Cu, Zn, Cs and Ba in the serum of FAP patients (mean age 38.5 +/- 8.3 years; duration of disease 4 +/- 2.6 years) in comparison with that of healthy individuals (mean age 36.2 +/- 9.2 years). On the other hand, these metals, except Cs, were found at high levels in the amyloid fibrils of FAP patients (mean age 55.8 +/- 9.2; duration of disease 6.5 +/- 1.3 years) compared with other metals. These findings firstly suggest that the mineral status could be a candidate factor, which participates in the wide spectrum of clinical pictures of FAP patients.
引用
收藏
页码:108 / 116
页数:9
相关论文
共 50 条
  • [21] Cardiac assessment of patients with familial amyloid polyneuropathy
    Gospodinova, M.
    Sarafov, S.
    Chamova, T.
    Guergelcheva, V.
    Tournev, I.
    Denchev, S.
    EUROPEAN HEART JOURNAL, 2015, 36 : 794 - 795
  • [22] Patisiran for the treatment of patients with familial amyloid polyneuropathy
    Rizk, M.
    Tuzmen, S.
    DRUGS OF TODAY, 2019, 55 (05) : 315 - 327
  • [23] Inflammatory profiling of patients with familial amyloid polyneuropathy
    Azevedo, Estefania P.
    Guimaraes-Costa, Anderson B.
    Bandeira-Melo, Christianne
    Chimelli, Leila
    Waddington-Cruz, Marcia
    Saraiva, Elvira M.
    Palhano, Fernando L.
    Foguel, Debora
    BMC NEUROLOGY, 2019, 19 (1)
  • [24] Inflammatory profiling of patients with familial amyloid polyneuropathy
    Estefania P. Azevedo
    Anderson B. Guimaraes-Costa
    Christianne Bandeira-Melo
    Leila Chimelli
    Marcia Waddington-Cruz
    Elvira M. Saraiva
    Fernando L. Palhano
    Debora Foguel
    BMC Neurology, 19
  • [25] Treatment of familial amyloid polyneuropathy
    Adams, David
    Samuel, Didier
    Slama, Michel
    PRESSE MEDICALE, 2012, 41 (09): : 793 - 806
  • [26] Pacing in familial amyloid polyneuropathy
    Vieira, C.
    Rebelo, A.
    Rocha, S.
    Torres, M.
    Gaspar, A.
    Ribeiro, S.
    Salome, N.
    Correira, A.
    EUROPEAN HEART JOURNAL, 2010, 31 : 417 - 417
  • [27] Vasculopathy in familial amyloid polyneuropathy
    Koike, H.
    Nishi, R.
    Ikeda, S.
    Kawagashira, Y.
    Iijima, M.
    Misumi, Y.
    Ando, Y.
    Ikeda, S. I.
    Katsuno, M.
    Sobue, G.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 475 - 476
  • [28] Pathology of familial amyloid polyneuropathy
    Koike, Haruki
    BRAIN PATHOLOGY, 2019, 29 : 61 - 61
  • [29] ECHOCARDIOGRAPHY IN FAMILIAL AMYLOID POLYNEUROPATHY
    FALK, R
    SIGSBEE, A
    LIBBEY, C
    SKINNER, M
    HUNTINGTON, M
    COHEN, A
    CIRCULATION, 1984, 70 (04) : 139 - 139
  • [30] Familial amyloid polyneuropathy 2003
    Munar-Qués, M
    MEDICINA CLINICA, 2003, 121 (03): : 100 - 101